Related Experiment Video

Updated: Jun 21, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy

Simon Zhen1, Sorina Nicoleta Bandelita2, Divaya Bhutani3

  • 1Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

American Journal of Hematology
|June 20, 2026
PubMed

of baseline characteristics, treatment regimens, hematologic and cardiac responses, and survival outcomes among 51 patients with Mayo stage IIIb AL amyloidosis treated with daratumumab-based frontline therapy.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...